Rusnano Teams Up With U.S. Fund Domain to Invest in Life Science

Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.

Rusnano, as the state-owned company is known, and Domain will invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said today in an e-mailed statement. The partners plan to bring in co-investors, according to the statement.